Stock Price, News, Quote and Profile of MILESTONE PHARMACEUTICALS IN(NASDAQ:MIST) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (4/26/2024, 7:03:48 PM)

After market: 1.58 +0.04 (+2.6%)

1.54

-0.04 (-2.53%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap81.85M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 39 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Company Info

MILESTONE PHARMACEUTICALS IN

420-1111 boul. Dr.-Frederik-Philips

MONTREAL QUEBEC H4M 2X6

P: 15143360444

CEO: Joseph Oliveto

Employees: 39

Website: https://www.milestonepharma.com

MIST News

20 days ago - Milestone Pharmaceuticals Inc.Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Data from this large safety-trial also published in The Journal of the American College of Cardiology...

a month ago - Milestone Pharmaceuticals Inc.Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on...

a month ago - BusinessInsiderMIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Milestone Pharmaceuticals (NASDAQ:MIST) just reported results for the fourth qu...

a month ago - InvestorPlaceMIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023

MIST stock results show that Milestone Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

a month ago - Milestone Pharmaceuticals Inc.Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on...

2 months ago - Milestone Pharmaceuticals Inc.Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its...

MILESTONE PHARMACEUTICALS IN (MIST)

Nasdaq Stock Screener

USA Stock Screener